Phase III meta-analysis of first-line chemo-immunotherapy in ES-SCLC: Survival benefit without detectable class-level differences
Adding a PD-1/PD-L1 inhibitor to platinum-etoposide in first-line ES-SCLC provides a consistent overall survival benefit, with no statistically detectable differences between PD-1 and PD-L1 inhibitor classes. This finding should be interpreted as absence of detectable class-level divergence rather than pharmacologic equivalence.
Authors
- D. Campana
- A.Di Odoardo
- A. Zappi
- M.G. Formelli
- E. Andrini
- G. Lamberti
Institutions
- University of Bologna (IT)
Publication Details
- Journal
- Lung Cancer
- Published
- 2026-03-17
- DOI
- https://doi.org/10.1016/j.lungcan.2026.109376
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00